BioX­cel scores an­oth­er win with re­for­mu­lat­ed Pfiz­er seda­tive, this time in an Alzheimer's symp­tom

Less than six months af­ter re­port­ing pos­i­tive Phase III re­sults for its lead pro­gram in treat­ing ag­i­ta­tion re­lat­ed to schiz­o­phre­nia and bipo­lar dis­or­der, small AI biotech BioX­cel fol­lowed up Tues­day with top-line da­ta in an ear­ly stage tri­al for ag­i­ta­tion in de­men­tia and Alzheimer’s dis­ease.

The ex­per­i­men­tal drug, known as BX­CL501, met its pri­ma­ry and sec­ondary end­points in the high­er evalu­able dose of a 54-pa­tient Phase Ib/II tri­al, BioX­cel an­nounced, in­duc­ing a sta­tis­ti­cal­ly sig­nif­i­cant calm­ing ef­fect com­pared to place­bo with no se­vere or se­ri­ous side ef­fects. With the da­ta in hand, BioX­cel plans to meet with the FDA some­time in the first half of 2021 be­fore launch­ing a late-stage study some­time af­ter­wards.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER